Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556439 · ClinicalTrials.gov registry record · Phase 2
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
A Phase 2 study of Giant Cell Arteritis and Takayasu's Arteritis, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 10
- Study locations
NCT00556439 is a Phase 2 study of Giant Cell Arteritis and Takayasu's Arteritis that has completed, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The registered enrollment target is 97 participants, below the 1,036-participant average among 7 other Giant Cell Arteritis trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT00556439, a Phase 2 study of Giant Cell Arteritis and Takayasu's Arteritis, has completed, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 10
- Study locations
Study Summary
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms. TAK specifically affects the aorta, the largest blood vessel in the body, and its branches. Therapies are available to improve the symptoms of GCA and TAK, but relapse often occurs, and better treatments are needed. Abatacept is a drug that interacts with certain cells in the body that are involved with GCA and TAK. This study will evaluate the effectiveness of abatacept in treating GCA and TAK and preventing disease relapse.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Abatacept
Study Locations (10)
Ontario
- St. Joseph's Hospital - Hamilton
- Mt. Sinai Hospital Toronto - Toronto
California
- Cedars-Sinai Medical Center - Los Angeles
Maryland
- Johns Hopkins Medical Center - Baltimore
Massachusetts
- Boston University - Boston
Minnesota
- Mayo Clinic - Rochester
New York
- Hospital for Special Surgery - New York
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2008-12 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)93 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00556439
The ClinicalTrials.gov registry entry for NCT00556439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,036-participant average among 7 other Giant Cell Arteritis trials with a reported enrollment target (91% lower). The listed sponsor is National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Giant Cell Arteritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00556439 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Ontario, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT00556439 about?
NCT00556439 is a clinical study titled "Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis". Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms. TAK specifically affects the aorta, the largest blood vessel in the body, and its branches. Therapies are available to improve the symptoms of GCA and T...
What is the current status of trial NCT00556439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2008-12. Estimated completion is 2015-08.
What conditions does trial NCT00556439 study?
This clinical trial studies the following conditions: Giant Cell Arteritis, Takayasu's Arteritis.
What interventions are being tested in trial NCT00556439?
The interventions under investigation include: Placebo (DRUG), Abatacept (DRUG).
Who is sponsoring clinical trial NCT00556439?
This trial is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00556439 being conducted?
This trial has 10 study locations across California, Maryland, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Giant Cell Arteritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
KPL-301 for Subjects With Giant Cell Arteritis
COMPLETED · Phase 2
-
Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)
RECRUITING
-
One-Time DNA Study for Vasculitis
RECRUITING
-
VCRC Tissue Repository
RECRUITING
-
Abatacept for the Treatment of Giant Cell Arteritis
RECRUITING · Phase 3
-
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.